Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 108Leukemia, Lymphocytic, Chronic, B-Cell 30Myelodysplastic Syndromes 23Leukemia, Biphenotypic, Acute 11Recurrence 10Lymphoma, Mantle-Cell 9Leukemia 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia, Myelomonocytic, Chronic 8Burkitt Lymphoma 8Waldenstrom Macroglobulinemia 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, B-Cell, Marginal Zone 7Lymphoma 7Hematologic Neoplasms 7Neoplasms 6Lymphoma, Large B-Cell, Diffuse 6Myeloproliferative Disorders 5Lymphoma, Non-Hodgkin 5Lymphoma, Follicular 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Multiple Myeloma 3Anemia, Refractory, with Excess of Blasts 3Sarcoma, Myeloid 2Myelodysplastic-Myeloproliferative Diseases 2Lymphoma, B-Cell 2Leukemia, Myeloid 2Immunoglobulin Light-chain Amyloidosis 2Blastic Plasmacytoid Dendritic Cell Neoplasm 2Blast Crisis 2

Interventions

venetoclax 1ruxolitinib 1pevonedistat 1Imatinib Mesylate 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hypereosinophilic Syndrome × venetoclax × 90 days × Clear all
NCT03862157 2026-03-11

Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
40 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hypereosinophilic Syndrome, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡